Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder

OBJECTIVE: Our aim was to determine whether serum C-X-C motif chemokine 5 (CXCL5) may serve as a diagnostic biomarker for relapsing-remitting multiple sclerosis (RRMS) as well as a marker that can be used to predict treatment response. METHODS: CXCL5 levels were measured by ELISA in sera of 20 RRMS...

Descripción completa

Detalles Bibliográficos
Autores principales: Karaaslan, Zerrin, Yilmaz, Vuslat, Yuceer, Hande, Sanli, Elif, Akcay, Halil Ibrahim, Kurtuncu, Murat, Turkoglu, Recai, Tuzun, Erdem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kare Publishing 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331241/
https://www.ncbi.nlm.nih.gov/pubmed/37435281
http://dx.doi.org/10.14744/nci.2022.77861
Descripción
Sumario:OBJECTIVE: Our aim was to determine whether serum C-X-C motif chemokine 5 (CXCL5) may serve as a diagnostic biomarker for relapsing-remitting multiple sclerosis (RRMS) as well as a marker that can be used to predict treatment response. METHODS: CXCL5 levels were measured by ELISA in sera of 20 RRMS patients under fingolimod treatment, 10 neuromyelitis optica spectrum disorder (NMOSD) patients, 15 RRMS patients presenting predominantly with spinal cord and optic nerve attacks (MS-SCON), and 14 healthy controls. RESULTS: Fingolimod treatment significantly reduced CXCL5 levels. CXCL5 levels were comparable among NMOSD and MS-SCON patients. CONCLUSION: Fingolimod might regulate the innate immune system. Serum CXCL5 measurement does not differentiate between RRMS and NMOSD.

Ejemplares similares